These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 35152722

  • 1. A CD123-specific chimeric antigen receptor augments anti-acute myeloid leukemia activity of Vγ9Vδ2 T cells.
    Zhang X, Ang WX, Du Z, Ng YY, Zha S, Chen C, Xiao L, Ng JY, Chng WJ, Wang S.
    Immunotherapy; 2022 Apr; 14(5):321-336. PubMed ID: 35152722
    [Abstract] [Full Text] [Related]

  • 2. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
    Morgan MA, Kloos A, Lenz D, Kattre N, Nowak J, Bentele M, Keisker M, Dahlke J, Zimmermann K, Sauer M, Heuser M, Schambach A.
    Viruses; 2021 Jul 14; 13(7):. PubMed ID: 34372571
    [Abstract] [Full Text] [Related]

  • 3. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
    Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, Hoffman L, Aguilar B, Chang WC, Bretzlaff W, Chang B, Jonnalagadda M, Starr R, Ostberg JR, Jensen MC, Bhatia R, Forman SJ.
    Blood; 2013 Oct 31; 122(18):3138-48. PubMed ID: 24030378
    [Abstract] [Full Text] [Related]

  • 4. Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia.
    Wang XY, Bian MR, Lin GQ, Yu L, Zhang YM, Wu DP.
    Eur J Haematol; 2024 Jan 31; 112(1):83-93. PubMed ID: 37712633
    [Abstract] [Full Text] [Related]

  • 5. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
    Thokala R, Olivares S, Mi T, Maiti S, Deniger D, Huls H, Torikai H, Singh H, Champlin RE, Laskowski T, McNamara G, Cooper LJ.
    PLoS One; 2016 Jan 31; 11(8):e0159477. PubMed ID: 27548616
    [Abstract] [Full Text] [Related]

  • 6. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
    Christodoulou I, Ho WJ, Marple A, Ravich JW, Tam A, Rahnama R, Fearnow A, Rietberg C, Yanik S, Solomou EE, Varadhan R, Koldobskiy MA, Bonifant CL.
    J Immunother Cancer; 2021 Dec 31; 9(12):. PubMed ID: 34896980
    [Abstract] [Full Text] [Related]

  • 7. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
    Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.
    Blood; 2017 Apr 27; 129(17):2395-2407. PubMed ID: 28246194
    [Abstract] [Full Text] [Related]

  • 8. [Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia].
    Wang ZZ, Lu Y, Xu YX, Xing HY, Tang KJ, Tian Z, Rao Q, Wang M, Xiong DS, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2020 Mar 14; 41(3):192-197. PubMed ID: 32311887
    [Abstract] [Full Text] [Related]

  • 9. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF, Turazzi N, Benedicenti F, Calabria A, Tenderini E, Tettamanti S, Giordano Attianese GM, Cooper LJ, Aiuti A, Montini E, Biondi A, Biagi E.
    Oncotarget; 2016 Aug 09; 7(32):51581-51597. PubMed ID: 27323395
    [Abstract] [Full Text] [Related]

  • 10. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
    Bonifant CL, Szoor A, Torres D, Joseph N, Velasquez MP, Iwahori K, Gaikwad A, Nguyen P, Arber C, Song XT, Redell M, Gottschalk S.
    Mol Ther; 2016 Sep 29; 24(9):1615-26. PubMed ID: 27401038
    [Abstract] [Full Text] [Related]

  • 11. Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models.
    Mu-Mosley H, Ostermann L, Muftuoglu M, Vaidya A, Bonifant CL, Velasquez MP, Gottschalk S, Andreeff M.
    Front Immunol; 2022 Sep 29; 13():880108. PubMed ID: 35615350
    [Abstract] [Full Text] [Related]

  • 12. Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells.
    Qin H, Edwards JP, Zaritskaya L, Gupta A, Mu CJ, Fry TJ, Hilbert DM, LaFleur DW.
    Mol Ther; 2019 Jul 03; 27(7):1262-1274. PubMed ID: 31043341
    [Abstract] [Full Text] [Related]

  • 13. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia.
    El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S, Aumann K, Clarson J, Vinnakota JM, Shoumariyeh K, Miething C, Lopez AF, Brown MP, Duyster J, Hein L, Manz MG, Hughes TP, White DL, Yong ASM, Zeiser R.
    Nat Commun; 2021 Nov 08; 12(1):6436. PubMed ID: 34750374
    [Abstract] [Full Text] [Related]

  • 14. Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells.
    You L, Han Q, Zhu L, Zhu Y, Bao C, Yang C, Lei W, Qian W.
    Front Immunol; 2020 Nov 08; 11():1787. PubMed ID: 32973749
    [Abstract] [Full Text] [Related]

  • 15. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.
    Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M.
    Blood; 2014 Apr 10; 123(15):2343-54. PubMed ID: 24596416
    [Abstract] [Full Text] [Related]

  • 16. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia.
    Arcangeli S, Rotiroti MC, Bardelli M, Simonelli L, Magnani CF, Biondi A, Biagi E, Tettamanti S, Varani L.
    Mol Ther; 2017 Aug 02; 25(8):1933-1945. PubMed ID: 28479045
    [Abstract] [Full Text] [Related]

  • 17. Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia.
    Sedloev D, Chen Q, Unglaub JM, Schanda N, Hao Y, Besiridou E, Neuber B, Schmitt A, Raffel S, Liu Y, Janssen M, Müller-Tidow C, Schmitt M, Sauer T.
    J Hematol Oncol; 2024 Sep 16; 17(1):85. PubMed ID: 39285441
    [Abstract] [Full Text] [Related]

  • 18. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
    Atilla PA, McKenna MK, Watanabe N, Mamonkin M, Brenner MK, Atilla E.
    Cytotherapy; 2022 Mar 16; 24(3):282-290. PubMed ID: 34955406
    [Abstract] [Full Text] [Related]

  • 19. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
    Caruso S, De Angelis B, Del Bufalo F, Ciccone R, Donsante S, Volpe G, Manni S, Guercio M, Pezzella M, Iaffaldano L, Silvestris DA, Sinibaldi M, Di Cecca S, Pitisci A, Velardi E, Merli P, Algeri M, Lodi M, Paganelli V, Serafini M, Riminucci M, Locatelli F, Quintarelli C.
    J Hematol Oncol; 2022 Nov 05; 15(1):163. PubMed ID: 36335396
    [Abstract] [Full Text] [Related]

  • 20. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
    Leyton JV, Hu M, Gao C, Turner PV, Dick JE, Minden M, Reilly RM.
    J Nucl Med; 2011 Sep 05; 52(9):1465-73. PubMed ID: 21816968
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.